Click
here to close Hello! We notice that
you are using Internet Explorer, which is not supported by Echinobase
and may cause the site to display incorrectly. We suggest using a
current version of Chrome,
FireFox,
or Safari.
Semin Thorac Cardiovasc Surg
2011 Jan 01;234:281-90. doi: 10.1053/j.semtcvs.2012.01.001.
Show Gene links
Show Anatomy links
Personalized therapy for non-small cell lung cancer: which drug for which patient?
Villaruz LC
,
Socinski MA
.
???displayArticle.abstract???
The elucidation of the molecular alterations in non-small cell lung cancer (NSCLC) and the development of molecularly targeted agents have permanently shifted NSCLC therapy to a personalized approach. In the metastatic setting, the addition of the anti-vascular endothelial growth factor monoclonal antibody, bevacizumab, to chemotherapy improves overall survival. The oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors, gefitinib and erlotinib, prolong progression-free survival in patients selected for the presence of an EGFR activating mutation. The monoclonal antibody to EGFR, cetuximab, improves survival in patients with metastatic NSCLC, and the inhibitor of the echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase (EML4-ALK) fusion protein, crizotinib, has resulted in an unprecedented overall survival advantage in patients harboring the EML4-ALK translocation. In the adjuvant setting, gefitinib has not been shown to improve patient survival outcomes; however, there are several ongoing clinical trials in the adjuvant setting evaluating the role of erlotinib, bevacizumab, and the MAGE-A3 and MUC1 vaccines. The realm of personalized lung cancer therapy also includes the study of chemotherapy selected on the basis of the pharmacogenetic profile of a patient's tumor. Several ongoing clinical trials in both the metastatic and adjuvant settings are studying the excision repair cross-complementing group 1 (ERCC1) protein, the ribonucleotide reductase subunit 1 (RRM1) protein, thymidylate synthase, and BRCA1 as predictors of chemotherapy response. This review will outline the current state of the art of personalized NSCLC therapy.
Abu-Shakra,
Cancer and autoimmunity: autoimmune and rheumatic features in patients with malignancies.
2001, Pubmed
Abu-Shakra,
Cancer and autoimmunity: autoimmune and rheumatic features in patients with malignancies.
2001,
Pubmed
Anders,
Poly(ADP-Ribose) polymerase inhibition: "targeted" therapy for triple-negative breast cancer.
2010,
Pubmed
Arriagada,
Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer.
2004,
Pubmed
Bean,
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib.
2007,
Pubmed
Bepler,
RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer.
2006,
Pubmed
Bergman,
In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant.
2005,
Pubmed
Brown,
Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract.
1993,
Pubmed
Brown,
Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer.
1995,
Pubmed
Burdett,
Chemotherapy in non-small cell lung cancer: an update of an individual patient data-based meta-analysis.
2005,
Pubmed
Butts,
Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer.
2005,
Pubmed
Chiarle,
The anaplastic lymphoma kinase in the pathogenesis of cancer.
2008,
Pubmed
Dahlberg,
Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599.
2010,
Pubmed
Davidson,
An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines.
2004,
Pubmed
De Plaen,
Structure, chromosomal localization, and expression of 12 genes of the MAGE family.
1994,
Pubmed
Douillard,
Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial.
2010,
Pubmed
Dziadziuszko,
Insulin-like growth factor receptor 1 (IGF1R) gene copy number is associated with survival in operable non-small-cell lung cancer: a comparison between IGF1R fluorescent in situ hybridization, protein expression, and mRNA expression.
2010,
Pubmed
Engelman,
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.
2007,
Pubmed
Ferrara,
The role of vascular endothelial growth factor in pathological angiogenesis.
1995,
Pubmed
Fossella,
Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group.
2003,
Pubmed
Fukuoka,
Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).
2011,
Pubmed
Gatzemeier,
Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial.
2007,
Pubmed
Giaccone,
Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1.
2004,
Pubmed
Herbst,
Lung cancer.
2008,
Pubmed
Herbst,
TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.
2005,
Pubmed
Herbst,
Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2.
2004,
Pubmed
Herbst,
Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial.
2011,
Pubmed
Hirschowitz,
Vaccines for lung cancer.
2006,
Pubmed
Ho,
Heterogeneity of mucin gene expression in normal and neoplastic tissues.
1993,
Pubmed
Hopwood,
Symptoms at presentation for treatment in patients with lung cancer: implications for the evaluation of palliative treatment. The Medical Research Council (MRC) Lung Cancer Working Party.
1995,
Pubmed
Johnson,
Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer.
2004,
Pubmed
Kawano,
PIK3CA mutation status in Japanese lung cancer patients.
2006,
Pubmed
Kelly,
Randomized phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non--small-cell lung cancer: a Southwest Oncology Group trial.
2001,
Pubmed
Kwak,
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
2010,
Pubmed
Lynch,
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
2004,
Pubmed
Lynch,
Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099.
2010,
Pubmed
Maemondo,
Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.
2010,
Pubmed
Mattern,
Association of vascular endothelial growth factor expression with intratumoral microvessel density and tumour cell proliferation in human epidermoid lung carcinoma.
1996,
Pubmed
Mitsudomi,
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.
2010,
Pubmed
Mok,
Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.
2009,
Pubmed
Mu,
Reaction mechanism of human DNA repair excision nuclease.
1996,
Pubmed
NSCLC Meta-Analyses Collaborative Group,
Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials.
2008,
Pubmed
NULL,
Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Non-small Cell Lung Cancer Collaborative Group.
1995,
Pubmed
Novellino,
A listing of human tumor antigens recognized by T cells: March 2004 update.
2005,
Pubmed
Olaussen,
DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.
2006,
Pubmed
Onozato,
Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers.
2009,
Pubmed
Paez,
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
2004,
Pubmed
Paik,
Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations.
2011,
Pubmed
Pao,
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.
2005,
Pubmed
Pardoll,
Does the immune system see tumors as foreign or self?
2003,
Pubmed
Pirker,
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial.
2009,
Pubmed
Quinn,
BRCA1 mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy.
2007,
Pubmed
Raez,
Lung cancer immunotherapy.
2005,
Pubmed
Rapp,
Chemotherapy can prolong survival in patients with advanced non-small-cell lung cancer--report of a Canadian multicenter randomized trial.
1988,
Pubmed
Reck,
Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil.
2009,
Pubmed
Reck,
Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL).
2010,
Pubmed
Rosell,
Ribonucleotide reductase messenger RNA expression and survival in gemcitabine/cisplatin-treated advanced non-small cell lung cancer patients.
2004,
Pubmed
Sancar,
Mechanisms of DNA excision repair.
1994,
Pubmed
Sandler,
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.
2006,
Pubmed
Scagliotti,
Phase III randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer.
2002,
Pubmed
Schiller,
Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.
2002,
Pubmed
Sequist,
Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.
2011,
Pubmed
Seto,
Prognostic value of expression of vascular endothelial growth factor and its flt-1 and KDR receptors in stage I non-small-cell lung cancer.
2006,
Pubmed
Sharma,
Epidermal growth factor receptor mutations in lung cancer.
2007,
Pubmed
Shaw,
Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.
2009,
Pubmed
Shepherd,
Erlotinib in previously treated non-small-cell lung cancer.
2005,
Pubmed
Simon,
Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer.
2007,
Pubmed
Soda,
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.
2007,
Pubmed
,
Echinobase
Soda,
A mouse model for EML4-ALK-positive lung cancer.
2008,
Pubmed
Takezawa,
Thymidylate synthase as a determinant of pemetrexed sensitivity in non-small cell lung cancer.
2011,
Pubmed
Taron,
BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer.
2004,
Pubmed
Thatcher,
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer).
NULL,
Pubmed
Yamamoto,
PIK3CA mutations and copy number gains in human lung cancers.
2008,
Pubmed
Zamble,
Repair of cisplatin--DNA adducts by the mammalian excision nuclease.
1996,
Pubmed
Zatloukal,
Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: a phase III randomized trial.
2003,
Pubmed
